Catabasis Pharma Bags $8M More for Series A
Massachusetts-based Catabasis Pharmaceuticals raised an additional $8 million in its Series A financing, now bringing its total funding for the round to $47.6 million. The company is developing an omega-3 conjugated compound for patients with severe hypertriglyceridemia. SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures all participated in the funding.
13 December 2011•1 min read
